Welcome to our dedicated page for enGene Holdings news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Holdings stock.
enGene Holdings Inc. (NASDAQ: ENGN) is a clinical-stage, non-viral genetic medicines company whose news flow centers on its lead investigational therapy, detalimogene voraplasmid, for high-risk non-muscle invasive bladder cancer (NMIBC). Company announcements frequently highlight clinical data from the ongoing Phase 2 LEGEND trial, regulatory interactions, and manufacturing readiness for this novel bladder-instilled genetic medicine.
Investors following ENGN news can expect updates on preliminary efficacy and safety results from the LEGEND pivotal cohort and additional cohorts, including complete response rates at various time points and treatment-related adverse event profiles. enGene also reports on changes to trial endpoints following discussions with the U.S. Food and Drug Administration, as well as participation in programs such as the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
News releases regularly cover capital markets activities, such as underwritten public offerings of common shares and pre-funded warrants, along with liquidity updates and financial results. Governance and leadership developments, including the appointment of new board members and the hiring of a Chief Medical Officer with extensive bladder cancer experience, are also disclosed through company press releases and related Form 8-K filings.
Because detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, regulatory and clinical milestones are key themes in enGene’s communications. For users tracking ENGN, this news page aggregates company-issued updates on clinical progress, FDA designations and programs, financing transactions, and corporate governance developments, offering a centralized view of material events that may shape the company’s development trajectory.
enGene (Nasdaq: ENGN) announced management will participate in four investor conferences between Feb 26 and Mar 11, 2026, including Oppenheimer, Leerink, Barclays and Citizens life sciences events. Formats include a presentation and multiple fireside chats.
A live webcast will be available on the company's Events and Presentations investor page and will be archived for 90 days.
enGene (Nasdaq: ENGN) announced that Ron Cooper, President and CEO, will speak in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Feb 11, 2026 at 2:30 p.m. ET. A live webcast will be available on the company's Investors "Events and Presentations" page and archived for 90 days.
enGene (Nasdaq: ENGN) amended its loan agreement with Hercules Capital to provide up to $125 million of debt financing, including $25 million funded at close and up to $100 million in additional tranches. The facility is non-dilutive, supports a planned BLA filing for detalimogene in H2 2026 and a potential commercial launch in 2027, and requires repayment of principal and accrued interest on or before January 1, 2030. Three $75 million of milestone-linked tranches and a discretionary final $25 million tranche complete the arrangement.
enGene (Nasdaq: ENGN) reported full‑year 2025 results and a business update on December 22, 2025. Key operational highlights include completion of enrollment in the LEGEND pivotal cohort at 125 patients and preliminary post‑amendment 6‑month complete response (CR) rate of 62% (n=37). The company was selected for the FDA CDRP program to support CMC readiness and plans a BLA filing in 2H 2026 for detalimogene.
Financially, enGene held $202.3M cash and marketable securities as of Oct 31, 2025 and raised $140.1M net in November, giving runway into 2H 2028. Full‑year operating expenses rose to $123.2M with a net loss of $117.3M (−$2.29/share).
enGene (Nasdaq: ENGN) announced that the FDA selected detalimogene voraplasmid for the Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program to support CMC interactions ahead of a potential Biologics License Application.
Detalimogene is an investigational non-viral gene therapy for high-risk, non-muscle invasive bladder cancer (NMIBC). The company says manufacturing has been scaled to commercial level and a BLA is planned for 2H 2026. Recent LEGEND pivotal-cohort data showed a 62% complete response rate at six months and safety data from 125 patients reported 42% treatment-related adverse events and 1.6% dose interruptions. Detalimogene holds RMAT and Fast Track designations.
enGene (Nasdaq: ENGN) announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 12:10 p.m. ET.
A live webcast of the presentation will be available on the company’s Investors > Events and Presentations page at www.engene.com and the archive will remain accessible for 90 days.
enGene (NASDAQ: ENGN) priced an underwritten public offering to raise approximately $130 million of gross proceeds through the sale of 12,558,823 common shares at $8.50 per share and 2,735,295 pre-funded warrants at $8.4999 each, before underwriting discounts and commissions. The offering includes a 30-day underwriter option to purchase up to 2,294,117 additional common shares. Closing is expected on or about November 14, 2025, subject to customary conditions. The securities will be offered under enGene’s effective Form S-3 shelf registration.
enGene (Nasdaq: ENGN) announced on November 12, 2025 that it has commenced an underwritten public offering of its common shares, with all shares to be sold by the company.
The company said it intends to grant underwriters a 30-day option to purchase up to 15% additional shares on the same terms. Jefferies, Leerink Partners and Wells Fargo Securities are joint book-running managers. The offering is made under the company’s effective Form S-3 shelf registration (File No. 333-283201). The final terms will be disclosed in a prospectus supplement filed with the SEC.
enGene (Nasdaq: ENGN) reported preliminary Phase 2 LEGEND pivotal-cohort data for detalimogene in high-risk, BCG-unresponsive NMIBC with CIS on November 11, 2025. Key interim results include a 63% complete response (CR) rate any time (N=62), 56% CR at 3 months (N=62), and 62% CR at 6 months (N=37). The Company completed pivotal enrollment at 125 patients, exceeding target by 25%.
Safety was favorable: 42% experienced a treatment-related adverse event (mainly Grade 1/2), 1.6% had dose interruptions, and 0.8% discontinued for TRAEs. enGene plans a BLA filing in H2 2026 with potential approval in 2027.
enGene (Nasdaq: ENGN) will host a live conference call and webcast on November 11, 2025 at 8:00 a.m. ET to present new preliminary data from the pivotal cohort of the ongoing LEGEND trial for detalimogene voraplasmid in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ.
Registration is required to receive dial‑in details; a live webcast link and a slide deck (posted ~30 minutes before the call) will be available on the company’s Events and Presentations page. A replay of the webcast will be accessible on the company website for one year.